Cyclerion and ironwood Results

You are searching for Cyclerion and ironwood, Below listing suggest some keywords related this keyword and listing websites with same content

Find Top Domain Names With

Top Keywords Suggestions

1 Cyclerion and ironwood

Most Searched Keywords

Domains Actived Recently

   » Shopinirvine.com (4 seconds ago)

   » Ua.org (41 seconds ago)

   » Rno.org (9 seconds ago)

   » Parkcrestdental.com (19 seconds ago)

   » Worryfreesites.com (11 seconds ago)

   » Jlcomputerservice.com (2 seconds ago)

   » Velammalnexus.com (9 seconds ago)

   » Realtyonegroupprosper.com (4 seconds ago)

   » Twinspeakeatgo.com (4 seconds ago)

Extract All Emails from Any Domain

Find All Domains on Any IP/ Domain

About 50 Websites Link


Ironwood Pharmaceuticals Completes Separation Of Cyclerion

Investor.ironwoodpharma.com   DA: 27 PA: 50 MOZ Rank: 77

  • Ironwood capitalizing on GI leadership and expertise in an effort to bring innovative therapies to patients – – Strategy centered on accelerating LINZESS ® (linaclotide) growth and advancing late-stage programs IW-3718 and MD-7246 – – Business poised to drive revenue growth and begin generating profits – Ironwood Pharmaceuticals, Inc
  • (NASDAQ: IRWD), a GI-focused …

Ironwood Pharmaceuticals, Inc.

Investor.ironwoodpharma.com   DA: 27 PA: 50 MOZ Rank: 78

Ironwood plans to complete the spin-off of Cyclerion (including the closing of the private placement) in early April 2019, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion with respect to the tax-free nature of the transaction, and final approval of Ironwood’s Board of Directors.

Ironwood Pharma Spins Off Cyclerion Therapeutics With 5

Biospace.com   DA: 16 PA: 50 MOZ Rank: 68

  • In late-February, Cambridge, Mass.-based Ironwood Pharmaceuticals announced it had entered into a private placement deal of up to $175 million that would be used to support its spinoff of Cyclerion Therapeutics
  • Today, Cyclerion has been launched on the second floor of a 200,000-square-foot, 3-story space on Binney Street, in Cambridge.
  • After the separation, no ongoing funding between

Cyclerion, The Planned R&D Spin-off Of Ironwood

Ir.cyclerion.com   DA: 16 PA: 50 MOZ Rank: 69

Ironwood plans to complete the spin-off of Cyclerion (including the closing of the private placement) in early April 2019, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion with respect to the tax-free nature of the transaction, and final approval of Ironwood’s Board of Directors.

Cyclerion Axes Another Program As Struggles Grow For Peter

Endpts.com   DA: 10 PA: 50 MOZ Rank: 64

  • Peter Hecht spun Ironwood into two different companies after an investor attack, but the results so far leave much to be desired
  • (Business Wire) October 14, 2020 10:19 AM EDT

Ironwood Pharmaceuticals Announces Chief

Ir.cyclerion.com   DA: 16 PA: 50 MOZ Rank: 71

  • Ironwood was founded in 1998 and is headquartered in Cambridge, Mass
  • We intend to separate into two independent, publicly traded companies (Ironwood and Cyclerion), a transaction expected to be completed in the first half of 2019.

Ironwood Pharmaceuticals Completes Separation Of Cyclerion

Bloomberg.com   DA: 17 PA: 50 MOZ Rank: 73

Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company – Ironwood capitalizing on GI leadership and expertise in

Ironwood Lays Off 35 Percent Of Workforce After Drug Fails

Bostonglobe.com   DA: 19 PA: 50 MOZ Rank: 76

  • Ironwood was founded in 1998 and had an initial public offering in 2010
  • In 2019 it spun off Cyclerion Therapeutics, a company focusing on treatments for …

Cyclerion Fails Sickle Cell Test, Prompting Pivot To CNS

Fiercebiotech.com   DA: 21 PA: 50 MOZ Rank: 79

  • Cyclerion spun off from Ironwood with two drugs in phase 2
  • Both drugs failed midphase trials, leaving IW-6463 as Cyclerion’s only other clinical-phase asset

Ironwood Lays Off One-third Of Staff After Heartburn Drug

Biopharmadive.com   DA: 21 PA: 50 MOZ Rank: 80

  • Ironwood has tried to focus its business on gastrointestinal disease, and last year spun off a slate of drugs aimed at metabolic, lung and orphan disorders into a company called Cyclerion Therapeutics
  • With the failure of heartburn drug IW-3718, it is now left with an empty drug pipeline.

Ironwood Pharmaceuticals Announces Chief Executive

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 80

We intend to separate into two independent, publicly traded companies (Ironwood and Cyclerion), a transaction expected to be completed in the first half of 2019.

Ironwood Pharmaceuticals Completes Separation Of Cyclerion

Biospace.com   DA: 16 PA: 50 MOZ Rank: 77

  • (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc

Ironwood Announces Effectiveness Of Cyclerion Form 10

Biotech-finances.com   DA: 24 PA: 50 MOZ Rank: 86

Thursday, March 14th 2019 at 8:54pm UTC – “When-issued” trading of CYCN expected to begin on Nasdaq on March 18,

As Ironwood Spinout Cyclerion Launches On The Nasdaq, CEO

Bizjournals.com   DA: 19 PA: 50 MOZ Rank: 82

Hecht rejected the idea, however, that the Ironwood-Cyclerion split, as well as the Ironwood executives' departures, is representative of anything bigger in …

Ironwood Announces Effectiveness Of Cyclerion Form 10

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 84

  • (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc

Ironwood, Traditional Drug Maker, Spins Off Edgy Kid

Bostonglobe.com   DA: 19 PA: 50 MOZ Rank: 84

In its new incarnation, Ironwood will have about 330 employees, having moved about 140 workers to Cyclerion and eliminated roughly 260 jobs since January of last year, Kaya said.

Leadership Team • Cyclerion

Cyclerion.com   DA: 17 PA: 17 MOZ Rank: 50

  • Our Vice President of Corporate Development, Todd Milne, PhD, brings more than 20 years of experience in the biopharma industry
  • Milne was a co-founder of Ironwood Pharmaceuticals where he held a number of scientific program and functional leadership roles, including leading sGC stimulator discovery and early development efforts at Ironwood.

Employee Matters Agreement, Dated As Of March 30, 2019, By

Contracts.justia.com   DA: 20 PA: 50 MOZ Rank: 87

  • Employee Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc
  • and Cyclerion Therapeutics, Inc from IRONWOOD PHARMACEUTICALS INC filed with the Securities and Exchange Commission.

Cyclerion Therapeutics Provides A Corporate And Pipeline

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 85

  • Cyclerion launched as an independent, publicly traded company on April 1, 2019
  • Cyclerion spun out of Ironwood Pharmaceuticals with a focus on …

Ironwood Names Proxy Brawler Denner To Its Board A Year

Fiercepharma.com   DA: 20 PA: 50 MOZ Rank: 89

Ironwood's R&D spinoff, dubbed Cyclerion, and concurrent job cuts aimed to offload between $3 million and $4 million in costs from the drugmaker's books as …

Ropes & Gray Represents Ironwood Pharmaceuticals In Its

Ropesgray.com   DA: 17 PA: 50 MOZ Rank: 87

  • Ropes & Gray represented Ironwood Pharmaceuticals, a GI-focused healthcare company, in connection with its tax-free spin-off of its soluble guanylate cyclase business, Cyclerion Therapeutics, Inc., and Cyclerion’s private placement of equity.
  • The separation was completed through distribution to Ironwood shareholders of one share of Cyclerion common stock for every 10 shares of Ironwood

Ironwood Pharmaceuticals : Announces Chief Executive

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 93

Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the leadership of each of Ironwood and Cyclerion following the separation, the strength and value thereof, and the leadership’s anticipated impact on Ironwood and Cyclerion’s businesses, growth, business strategies, pipeline

Ironwood And Cyclerion Name Women To Chair Boards – ISPE

Ispeboston.org   DA: 18 PA: 50 MOZ Rank: 90

  • The separation of Ironwood Pharmaceuticals into two independent, publicly traded companies, Ironwood and Cyclerion Therapeutics, first announced in May 2018, is on track to be completed during the first half of 2019; and both companies have named women to lead their new boards of directors
  • Julie McHugh will serve as chair of the new Ironwood […]

Ironwood Spinout Nosedives, Plots Layoffs After Twin Phase

Fiercebiotech.com   DA: 21 PA: 50 MOZ Rank: 94

  • Ironwood spinout Cyclerion Therapeutics will lay off 30 of its 135 employees after one of its lead programs fell short in phase 2 studies in heart failure and diabetic kidney disease

Maturing Ironwood Is Spinning Off Cyclerion, Its Edgy

Statnews.com   DA: 16 PA: 50 MOZ Rank: 90

  • Maturing Ironwood is spinning off Cyclerion, its edgy, risk-taking kid brother
  • Ironwood Pharmaceuticals, one of Cambridge’s largest biotech firms, is …

Ironwood Pharmaceuticals Completes Separation Of Cyclerion

M.insidertracking.com   DA: 21 PA: 50 MOZ Rank: 96

  • (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc
  • Ironwood is executing on its strategy to drive growth as a GI-focused company, building upon its commercial success with LINZESS and advancing its late-stage, first

Ironwood Swipes AZ Commercial Hotshot Mark Mallon To Fill

Fiercepharma.com   DA: 20 PA: 50 MOZ Rank: 96

  • The first week of 2019 looks a lot like 2018 in at least one regard: A Big Pharma company’s commercial head is on the move
  • This time it’s Mark Mallon, AstraZeneca’s EVP of …

Ironwood And Cyclerion Income Tax Deductions In Respect Of

Lawinsider.com   DA: 18 PA: 50 MOZ Rank: 95

  • Ironwood and Cyclerion Income Tax Deductions in Respect of Certain Equity Awards and Compensation
  • Unless otherwise required by a change in applicable Law following the date of this Agreement or by a

J.P. Morgan 2018 Healthcare Conference

S2.q4cdn.com   DA: 12 PA: 50 MOZ Rank: 90

  • Ironwood and Cyclerion: pivotal moment to grow two industry-leading companies and unlock shareholder value
  • Late-stage pre-clinical development
  • expected to: Build a leading GI franchise

Ironwood 4Q And Full Year 2018 Investor Update

S2.q4cdn.com   DA: 12 PA: 50 MOZ Rank: 91

business and operations of Ironwood and Cyclerion and any benefits or costs of the separation; the status of Cyclerion’s proposed financing and the duration of the cash runway that will be provided by the financing; the leadership and boards of each of Ironwood and Cyclerion following the separation and the strength and value thereof; the

After 21 Years And A Spinoff, Profitability Finally Arrives

Cfo.com   DA: 11 PA: 50 MOZ Rank: 91

  • Ironwood received such a letter, and KPMG concluded that the spinoff would be tax-free
  • “It was a huge win for us,” emphasizes Consylman
  • If the spinoff had not qualified for tax-free treatment, Ironwood would have recognized a gain reflecting the value of the Cyclerion

Peter M Hecht, Cyclerion Therapeutics Inc: Profile And

Bloomberg.com   DA: 17 PA: 23 MOZ Rank: 71

  • Peter M Hecht is Chief Executive Officer at Cyclerion Therapeutics Inc
  • See Peter M Hecht's compensation, career history, education, & memberships

IRONWOOD PHARMACEUTICALS INC

Tipranks.com   DA: 16 PA: 38 MOZ Rank: 86

IRONWOOD PHARMACEUTICALS INC, Ten Percent Owner at Cyclerion Therapeutics (CYCN), is currently unranked, see this insider's latest transactions.

Cyclerion Therapeutics, Inc.

Lawinsider.com   DA: 18 PA: 43 MOZ Rank: 94

  • View Cyclerion Therapeutics, Inc
  • contracts and agreements from SEC filings
  • Including company executives, business partners, clauses and more.

Cyclerion Therapeutics Trading Near Cash; Offers A

Forbes.com   DA: 14 PA: 50 MOZ Rank: 98

  • Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to …

Ironwood Pharmaceuticals Announces Mark Mallon As CEO

Talent4boards.com   DA: 17 PA: 50 MOZ Rank: 15

  • Ironwood was founded in 1998 and is headquartered in Cambridge, Mass
  • We intend to separate into two independent, publicly traded companies (Ironwood and Cyclerion), a transaction expected to be completed in the first half of 2019
  • For more, visit www.ironwoodpharma.com

Cyclerion Therapeutics Reports Second Quarter 2019

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 14

Basis of presentation: Cyclerion’s unaudited consolidated balance sheet as of June 30, 2019, and results of operations for the second quarter ended June …

Praliciguat Inhibits Progression Of Diabetic Nephropathy

Journals.physiology.org   DA: 23 PA: 36 MOZ Rank: 96

  • Praliciguat was synthesized at Cyclerion Therapeutics
  • For the ZSF1 experiment, praliciguat was incorporated into Purina 5008 rodent chow by ResearchDietsat 8.3, 25, and83mgofpraliciguat per kilogram chow (dose equivalent to 1, 3, and 10 mg·kg 1·day , respectively)

Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call

Fool.com   DA: 12 PA: 50 MOZ Rank: 100

  • Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Q3 2020 Earnings Call Nov 6, 2020, 4:30 p.m
  • Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator

Recently Analyzed Sites

Shopinirvine.com (4 seconds ago)

Ua.org (41 seconds ago)

Rno.org (9 seconds ago)

Parkcrestdental.com (19 seconds ago)

Worryfreesites.com (11 seconds ago)

Jlcomputerservice.com (2 seconds ago)

Velammalnexus.com (9 seconds ago)

Twinspeakeatgo.com (4 seconds ago)

Palizgol.com (45 seconds ago)

Digitale-nieuwsbrief.com (8 seconds ago)

Game-finder.com (17 seconds ago)

Faymortgage.com (17 seconds ago)

Texanscanstaff.org (9 seconds ago)

Petemillerlaw.com (0 seconds ago)

Righteousfur.com (9 seconds ago)

Tpni.com (23 seconds ago)